Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry ...

Abstract Background Severe asthma (SA) may require frequent courses or chronic use of oral corticosteroids (OCS), inducing many known side effects and complications. Therefore, it is important to identify risk factors of chronic use of OCS in SA, considering the heterogeneity of clinical and inflammatory asthma phenotypes. Another aim of the present analysis is to characterize a subpopulation of severe asthmatics, in whom blood eosinophil counts (BEC) remain elevated despite chronic OCS treatment. Methods In a cross-sectional analysis of 982 SA patients enrolled in the Belgian Severe Asthma Re... Mehr ...

Verfasser: Graff, S.
Vanwynsberghe, S.
Brusselle, G.
Hanon, S.
Sohy, C.
Dupont, L. J.
Peche, R.
Michils, A.
Pilette, C.
Joos, G.
Louis, R. E.
Schleich, F. N.
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Verlag/Hrsg.: figshare
Schlagwörter: Medicine / Microbiology / FOS: Biological sciences / Genetics / Molecular Biology / Pharmacology / Ecology / Immunology / FOS: Clinical medicine / Biological Sciences not elsewhere classified / Developmental Biology / Marine Biology / Science Policy / Infectious Diseases / FOS: Health sciences
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-28885351
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dx.doi.org/10.6084/m9.figshare.c.5090338.v1

Abstract Background Severe asthma (SA) may require frequent courses or chronic use of oral corticosteroids (OCS), inducing many known side effects and complications. Therefore, it is important to identify risk factors of chronic use of OCS in SA, considering the heterogeneity of clinical and inflammatory asthma phenotypes. Another aim of the present analysis is to characterize a subpopulation of severe asthmatics, in whom blood eosinophil counts (BEC) remain elevated despite chronic OCS treatment. Methods In a cross-sectional analysis of 982 SA patients enrolled in the Belgian Severe Asthma Registry (BSAR) between March 2009 and February 2019, we investigated the characteristics of the OCS treated patients with special attention to their inflammatory profile. Results At enrollment, 211 (21%) SA patients were taking maintenance OCS (median dose: 8 [IQR: 5–10]) mg prednisone equivalent). BEC was high (> 400/mm3) in 44% of the OCS treated population. Multivariable logistic regression analysis showed that ...